Amneal Pharmaceuticals (NYSE:AMRX- Get a rating) announced its quarterly results on Friday. The company reported earnings per share (EPS) of $0.19 for the quarter, reaching the consensus estimate of $0.19, Briefing.com reports. Amneal Pharmaceuticals had a return on equity of 61.08% and a net margin of 0.68%. The company posted revenue of $559.40 million in the quarter, versus a consensus estimate of $534.44 million. In the same period a year earlier, the company had earned earnings per share of $0.23. The company’s revenue for the quarter increased by 4.5% compared to the same quarter last year. Amneal Pharmaceuticals updated its FY2022 guidance to EPS of $0.65-0.70 and its FY22 guidance to EPS of $0.65-0.70.
Amneal Pharmaceuticals Price Performance
Amneal Pharmaceuticals stock traded down $0.28 at midday on Friday, hitting $3.18. 1,792,102 shares of the company were traded, against an average volume of 683,602. The company has a fifty-day simple moving average of $3.32 and a 200-day simple moving average of $3.84. Amneal Pharmaceuticals has a 12-month low of $2.90 and a 12-month high of $5.99. The company has a debt ratio of 7.11, a current ratio of 2.35 and a quick ratio of 1.57. The company has a market capitalization of $963.30 million, a PE ratio of 35.33, a PEG ratio of 0.22 and a beta of 1.24.
Hedge funds weigh on Amneal Pharmaceuticals
Several hedge funds and other institutional investors have recently changed their holdings in the company. Sei Investments Co. increased its stake in Amneal Pharmaceuticals by 17.7% in Q1. Sei Investments Co. now owns 20,553 shares of the company worth $62,000 after purchasing an additional 3,096 shares during the period. Mirabella Financial Services LLP bought a new position in shares of Amneal Pharmaceuticals in the first quarter worth $63,000. Atria Wealth Solutions Inc. bought a new position in Amneal Pharmaceuticals in the first quarter worth $75,000. Virtu Financial LLC acquired a new stake in Amneal Pharmaceuticals during the first quarter worth approximately $109,000. Finally, Captrust Financial Advisors increased its position in Amneal Pharmaceuticals by 23,158.8% during the first quarter. Captrust Financial Advisors now owns 55,821 shares of the company valued at $233,000 after purchasing an additional 55,581 shares during the period. Institutional investors hold 38.54% of the company’s shares.
Changes to analyst ratings
Separately, Barclays lowered its target price on Amneal Pharmaceuticals from $8.00 to $7.00 in a Thursday, April 28 research note.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The Company operates through three segments: Generics, Specialties and AvKARE. The Generics segment develops, manufactures and markets complex oral solids, injectables, ophthalmics, liquids, topicals, capsules, inhalants and transdermals in a range of therapeutic categories.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Before you consider Amneal Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Amneal Pharmaceuticals was not on the list.
While Amneal Pharmaceuticals currently has an “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here